Lemborexant and related sleep medicines present potential for treating tau-related problems, together with Alzheimer’s illness.
New analysis from Washington College Faculty of Drugs in St. Louis exhibits {that a} generally used sleep remedy can restore regular sleep patterns and defend mice from the mind harm linked to neurodegenerative circumstances resembling Alzheimer’s illness. The drug, lemborexant, blocks the buildup of an irregular type of the tau protein within the mind, thereby lowering the irritation and mobile harm that tau usually causes in Alzheimer’s.
The findings point out that lemborexant, together with different medicines that act in the same means, may maintain promise for treating or stopping tau-related harm in a number of neurodegenerative problems, together with Alzheimer’s illness, progressive supranuclear palsy, corticobasal syndrome, and sure types of frontotemporal dementia.
The research was not too long ago printed within the journal Nature Neuroscience.
Linking sleep loss and tau buildup
“We’ve identified for a very long time that sleep loss is a threat issue for Alzheimer’s illness,” stated senior writer David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology at WashU Drugs. “On this new research, we’ve got proven that lemborexant improves sleep and reduces irregular tau, which seems to be a principal driver of the neurological harm that we see in Alzheimer’s and several other associated problems. We’re hopeful this discovering will result in additional research of this sleep remedy and the event of latest therapeutics which may be more practical than present choices both alone or together with different obtainable therapies.
“The antibodies to amyloid that we now use to deal with sufferers with early, delicate Alzheimer’s dementia are useful, however they don’t gradual the illness down as a lot as we wish,” he added. “We want methods to cut back the irregular tau buildup and its accompanying irritation, and any such sleep help is price additional. We’re fascinated about whether or not going after each amyloid and tau with a mix of therapies could possibly be more practical at slowing or stopping the development of this illness.”
Testing lemborexant in mouse fashions
Holtzman and his colleagues have been among the many first to display that poor sleep is a threat issue for Alzheimer’s illness, intently linked to the buildup of proteins resembling amyloid and tau. In earlier research utilizing mice genetically predisposed to develop these protein deposits, they confirmed that sleep loss accelerates this buildup. Their latest analysis revealed that bettering sleep in these mice with lemborexant decreased tau tangles and lowered the extent of nerve cell dying usually related to Alzheimer’s illness.
Tau protein accumulates within the mind in a number of neurological problems, together with Alzheimer’s, the place it triggers irritation and the degeneration of neurons. Holtzman’s staff, with Samira Parhizkar, PhD, as first writer, investigated lemborexant partly as a result of it targets mind areas particularly weak to irregular tau buildup. Importantly, it doesn’t intervene with motor coordination, a difficulty usually raised when contemplating sleep medicines for individuals with dementia.
Mechanism of motion and comparisons
Lemborexant belongs to a category of three FDA-approved sleep medicines that act as orexin receptor antagonists. Orexins are small proteins that regulate sleep by binding to receptors on cell surfaces. By blocking each orexin receptor varieties (1 and a couple of), lemborexant disrupts orexin exercise, influencing the sleep-wake cycle and associated processes resembling urge for food regulation.
The pharmaceutical firm Eisai offered lemborexant for these research as a part of a analysis collaboration with WashU Drugs targeted on growing revolutionary therapies for Alzheimer’s illness, Parkinson’s illness, and different neurodegenerative illnesses.
In mice genetically susceptible to dangerous tau buildup, lemborexant decreased mind harm in contrast with management mice. For instance, these receiving lemborexant confirmed 30% to 40% bigger quantity within the hippocampus — part of the mind necessary for forming reminiscences — in contrast with management mice and people receiving a unique sleep drug, zolpidem, which belongs to a unique class of medicine. Zolpidem elevated sleep however had not one of the protecting results in opposition to tau accumulation within the mind that have been seen with lemborexant, suggesting that the kind of sleep help — orexin receptor antagonist — is essential in producing the neuroprotective results. The researchers additionally discovered that the helpful results have been solely seen in male mice, which they’re nonetheless working to grasp.
Regular tau is necessary in sustaining the construction and performance of neurons. When wholesome, it carries a small variety of chemical tags referred to as phosphate teams. However when tau picks up too many of those chemical tags, it might clump collectively, resulting in irritation and nerve cell dying. The authors discovered that by blocking orexin receptors, lemborexant prevents extra tags from being added to tau, serving to tau preserve its wholesome roles within the mind.
Holtzman stated his staff is constant to discover the explanations lemborexant therapy’s neuroprotective results have been seen solely in male mice. He speculated that the intercourse discrepancy could possibly be because of the remark that feminine mice with the identical genetic predisposition to tau accumulation developed less-severe neurodegeneration in contrast with male mice. With much less harm to start with, potential helpful results of the drug may have been smaller and harder to detect.
Reference: “Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse mannequin of tauopathy” by Samira Parhizkar, Xin Bao, Wei Chen, Nicholas Rensing, Yun Chen, Michal Kipnis, Sihui Tune, Grace Gent, Eric Tycksen, Melissa Manis, Choonghee Lee, Javier Remolina Serrano, Megan E. Bosch, Emily Franke, Carla M. Yuede, Eric C. Landsness, Michael Wong and David M. Holtzman, 27 Could 2025, Nature Neuroscience.
DOI: 10.1038/s41593-025-01966-7
This work was supported by the Nationwide Institutes of Well being (NIH), grant numbers P01NS074969, RF1NS090934 and RF1AG061776; the JPB Basis; the Alzheimer’s Affiliation, grant quantity AARF-21-850865; the Rainwater Basis, and a COBRAS Feldman Fellowship.
Holtzman is an inventor on a patent licensed by Washington College to C2N Diagnostics on the therapeutic use of anti-tau antibodies. Holtzman cofounded and is on the scientific advisory board of C2N Diagnostics.
